Description
Continuous Glucose Monitoring (CGM) Systems Market Overview
The Continuous Glucose Monitoring (CGM) Systems Market is expected to grow at a CAGR of 17.0%, with an estimated value of around USD 12.63 billion in 2024, USD 12.4 billion in 2025, and USD 47.1 billion by 2034.
The growing adoption of CGM systems can be attributed to their numerous benefits over traditional glucose monitoring methods. These devices offer real-time alerts for high and low blood sugar levels, reducing the risk of dangerous fluctuations. Additionally, CGM systems provide valuable insights into how food, exercise, and medication affect blood sugar levels, enabling users to make timely adjustments for better management.
Furthermore, technological advancements in CGM systems have made them more user-friendly and accurate, attracting a wider consumer base. The integration of smartphone apps and cloud-based data storage allows for seamless monitoring and data sharing with healthcare providers, enhancing remote patient care and management.
Overall, the increasing awareness about diabetes management and the benefits of CGM systems have fueled the demand for these devices in the market. With continuous innovation and improvements in accuracy and reliability, CGM systems are set to play a significant role in empowering individuals with diabetes to take control of their health.
Continuous Glucose Monitoring (CGM) Systems Market Dynamics
Drivers
One of the significant drivers of the CGM systems market is the increasing prevalence of diabetes worldwide. With more people being diagnosed with diabetes, there is a growing demand for better ways to monitor glucose levels effectively. CGM systems provide real-time data, allowing individuals to make informed decisions about their diet, exercise, and insulin dosage.
Another driver of the CGM systems market is the technological advancements in healthcare. CGM systems use sensors to continuously monitor glucose levels, eliminating the need for painful finger pricks. This non-invasive approach to glucose monitoring has increased the adoption of CGM systems among individuals with diabetes.
Restraints
Despite the numerous benefits of CGM systems, cost can be a significant restraint for many individuals. CGM systems can be expensive, making them inaccessible to some patients. Insurance coverage for CGM systems varies, and not all patients may have the financial means to afford this technology.
Challenges
One of the challenges facing the CGM systems market is the accuracy of the devices. While CGM systems provide real-time data, there have been instances of inaccuracies in glucose readings. Manufacturers are continuously working to improve the accuracy of CGM systems to ensure that patients can rely on the information provided.
Opportunities
The growing demand for wearable technology presents a significant opportunity for the CGM systems market. As individuals become more health-conscious and tech-savvy, there is a greater interest in devices that can monitor health metrics continuously. CGM systems have the potential to cater to this market demand by providing a convenient and efficient way to track glucose levels.
List of Key Players
- Dexcom, Inc.
- Abbott Laboratories (FreeStyle Libre)
- Medtronic plc
- Senseonics Holdings, Inc.
- Ypsomed AG
- Eli Lilly and Company
- Roche (Accu‑Chek Type CGM)
- Menarini Diagnostics
- Signos, Inc.
- Tandem Diabetes Care
- Insulet Corporation
- Bigfoot Biomedical
- Bio-RFID (Know Labs)
- Indigo Diabetes
- GlySens Incorporated
- Ultrahuman (M1 CGM)
- Profusa, Inc.
- Liom (Spiden)
- Occuity
- Roche Diagnostics
Recent Developments:
April 10, 2025 – Dexcom, Inc. received FDA clearance for the Dexcom G7 15‑Day CGM system, a wearable sensor with 15.5‑day wear time and 8.0% MARD.
March 2024 – Dexcom received FDA marketing clearance for its Stelo OTC CGM system targeting early-stage diabetics .
January 2024 – Medtronic plc announced CE Mark approval for its MiniMed 780G with Simplera Sync, featuring a simplified sensor insertion and smaller size.
September 2024 – Senseonics Holdings received FDA clearance for its Eversense 365 iCGM, a 365-day implantable CGM system
Continuous Glucose Monitoring (CGM) Systems Market Segmentation
By Component
- Sensors
- Transmitters
- Receivers
By End User
- Hospitals & Clinics
- Home Care Settings
- Diabetes Management Centers
- Pharmacies & Retail Outlets
By Device Type
- Personal CGM
- Professional CGM
- Fully Integrated/Embedded CGM
By Technology
- Transcutaneous (Wearable)
- Implantable
Regional Market Insights: A Breakdown by Region
North America
North America dominates the CGM systems market, with a high adoption rate among individuals with diabetes. The region’s advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness about diabetes management have contributed to the widespread use of CGM systems. Major players in the market, such as Dexcom and Medtronic, have established a strong presence in North America, offering innovative products to cater to the growing demand.
Europe
Europe is another key market for CGM systems, with a growing emphasis on preventive healthcare and chronic disease management. Countries like Germany, the UK, and France have witnessed a steady increase in the adoption of CGM systems due to the rising prevalence of diabetes. Regulatory support and technological advancements in the region have further fueled the growth of the CGM systems market in Europe.
Asia Pacific
The Asia Pacific region is poised for significant growth in the CGM systems market, driven by the increasing incidence of diabetes and improving healthcare infrastructure. Countries like China, India, and Japan are experiencing a surge in demand for CGM systems as more individuals seek advanced tools for diabetes management. Local players are also entering the market, offering cost-effective solutions tailored to the needs of the Asian population.
Latin America
Latin America is emerging as a promising market for CGM systems, with a growing focus on improving diabetes care and management. Countries like Brazil and Mexico are witnessing increased awareness about the benefits of CGM systems, leading to greater adoption among healthcare providers and patients. The region’s expanding economy and rising healthcare expenditure are expected to drive the growth of the CGM systems market in Latin America.
Middle East and Africa
The Middle East and Africa region are gradually embracing CGM systems as part of their efforts to combat the rising burden of diabetes. Improving access to healthcare services, rising disposable income, and government initiatives to promote diabetes management are driving the adoption of CGM systems in the region. Companies are partnering with local distributors to expand their presence and cater to the unique needs of the Middle Eastern and African market.
Target Audience
Endocrinologists & Diabetologists
Primary Care Physicians
Hospitals & Clinics
Home Healthcare Providers
Pharmacies & Retail Outlets
Health Insurance & Payers
Diabetes Management Platforms & Tech Firms
Regulatory Authorities
Clinical Researchers & Academic Institutions
Investors & Healthcare Equity Firms
